Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onward Medical NVSTU:63E -0.35%40 Debt-to-Equity is 0.20 as of Jun. 2026, which is at its 10-year median of 0.20. GuruFocus rates STU:63E with a GF Score™ of 40/100 and a GF Value™ of €119.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 964 Biotechnology companies, Onward Medical NV ranks worse than 53.22% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Onward Medical NV's Debt-to-Equity or its related term are showing as below:
STU:63E'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.74 Med: 0.2 Max: 0.94
Current: 0.19
During the past 7 years, the highest Debt-to-Equity Ratio of Onward Medical NV was 0.94. The lowest was -2.74. And the median was 0.20.
STU:63E's Debt-to-Equity is ranked worse than 53.22% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs STU:63E: 0.19
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Onward Medical NV Debt-to-Equity Related Terms
Onward Medical NV Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Onward Medical NV's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:63E vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Onward Medical NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onward Medical NV Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Onward Medical NV's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Onward Medical NV's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onward Medical NV (STU:63E) has a Debt-to-Equity of 0.20 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Onward Medical NV and its competitors. This is near median its historical median of 0.20. According to the industry distribution chart, Onward Medical NV ranks #513 out of 964 companies in the Biotechnology industry, placing it in the top 53.2%.
Is Onward Medical NV's Debt-to-Equity too high?
Onward Medical NV's current Debt-to-Equity of 0.20 is near median its 10-year median of 0.20. The Biotechnology industry median Debt-to-Equity is 0.16. Onward Medical NV's value of 0.20 is 29% above this industry median. Based on the distribution chart, Onward Medical NV ranks #513 out of 964 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Onward Medical NV has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Onward Medical NV's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Onward Medical NV ranks #513 out of 964 companies for Debt-to-Equity. This places Onward Medical NV in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Onward Medical NV's value of 0.20 is 29% above this benchmark. While the company's 10-year median is 0.20 vs. the industry median of 0.16, Onward Medical NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onward Medical NV's current Debt-to-Equity of 0.20 is 29% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Onward Medical NV and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onward Medical NV's current Debt-to-Equity is 0.20, which is near median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onward Medical NV stock overvalued right now?
Based on GuruFocus' analysis, Onward Medical NV (STU:63E) is currently considered Possible Value Trap. The stock's GF Value™ is €119.29, compared to a current price of €2.88 — trading 97.6% below its estimated fair value. The current Debt-to-Equity is 0.20, which is near median its 10-year median of 0.20 and 29% above the Biotechnology industry median of 0.16. Onward Medical NV's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Onward Medical NV (STU:63E), the current Debt-to-Equity is 0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Onward Medical NV (STU:63E) Overvalued in 2026?
Based on GuruFocus' analysis, Onward Medical NV stock appears to be undervalued.
The current stock price of €2.88 is trading 97.6% below its estimated GF Value™ of €119.29.
GuruFocus considers Onward Medical NV to be Possible Value Trap.
Key valuation signals for STU:63E:
Debt-to-Equity: 0.20 (near median its 10-year median of 0.20)
GF Value™: €119.29 vs. price of €2.88 (97.6% below fair value)
Industry Position: 29% above the Biotechnology median (#513 of 964)
No single metric tells the full story. See the STU:63E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Onward Medical NV is developing and commercializing therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company's technology platforms are based on ONWARD ARC Therapy (ARC Therapy), targeted, programmed electrical stimulation of the spinal cord designed to restore movement, independence, and health in people with SCI.
40GF Score
Get the complete analysis for STU:63E
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:63E has been successfully added to your 
